Impact of Morning-Evening Supplementing Therapy on Pulmonary Function and Recurrence Rate in Patients with Stable Chronic Obstructive Pulmonary Disease of Lung-Kidney Deficiency Type
10.13359/j.cnki.gzxbtcm.2025.08.008
- VernacularTitle:朝夕补益法对慢性阻塞性肺疾病稳定期肺肾亏虚证患者肺功能及复发率的影响
- Author:
Fenru LI
1
;
Qian SU
;
Chang LI
Author Information
1. 广州中医药大学研究生院,广东 广州 510006
- Keywords:
chronic obstructive pulmonary disease(COPD);
lung-kidney deficiency syndrome;
morning-evening supplementing therapy;
Buzhong Yiqi Pills;
Liuwei Dihuang pills;
Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation;
pulmon
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(8):1882-1889
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of morning-evening supplementing therapy,a therapy by tonification according to the alteration of daily yang-qi in the human body and the nature proposed by practitioner XUE Ji in Ming Dynasty,on the pulmonary function and recurrence rate in patients with stable chronic obstructive pulmonary disease(COPD)of lung-kidney deficiency type.Methods Ninety stable COPD patients with lung-kidney deficiency syndrome treated at Chongqing Hospital of the First Affiliated Hospital of Guangzhou University of Chinese Medicine from January 2023 to August 2023 were equally randomized into two groups using a random number table,45 cases in the control group and 45 cases in the treatment group.Both groups received Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation alone,and the treatment group received additional morning-evening supplementing therapy by using Buzhong Yiqi Pills in the morning and Liuwei Dihuang Pills in the evening.The treatment for the two groups covered 3 months.Before and after treatment,changes in the outcomes of traditional Chinese medicine(TCM)syndrome scores,COPD Assessment Test(CAT)scores,serum magnesium ion(Mg2?)level,and pulmonary function parameters[percentage of the forced expiratory volume in one second to the predicted volume(FEV1%),percentage of maximum voluntary ventilation to the predicted volume(MVV%),and peak expiratory flow(PEF)]in the two groups were observed.After treatment,clinical efficacy was evaluated,and the frequency of acute exacerbation and hospitalization within one-year follow-up was compared in the two groups.Results(1)There were 6 patients falling off during the trial,and 84 cases were eventually included,with 41 cases in the treatment group and 43 cases in the control group.(2)After 3 months of treatment,the total effective rate of the treatment group was 85.37%(35/41),and that of the control group was 69.77%(30/43).The intergroup comparison(tested by chi-square test)showed that the efficacy of the treatment group was significantly superior to that of the control group(P＜0.01).(3)After treatment,TCM syndrome scores and CAT scores in the two groups were lower than those before treatment(P＜0.01),and the decrease in the treatment group was significantly superior to that in the control group(P＜0.01).(4)After treatment,pulmonary function parameters of FEV1%,MVV%and PEF in the two groups were improved when compared with those before treatment(P＜0.01),and the improvement in the treatment group was superior to that in the control group(P＜0.05 or P＜0.01).(5)After treatment,the serum Mg2+level of the two groups was higher than that before treatment(P＜0.01),and the increase in the treatment group was superior to that in the control group(P＜0.01).(6)The one-year follow-up after treatment showed that the frequency of acute exacerbation and hospitalization in the treatment group was decreased compared to that in the control group(P＜0.05).Conclusion Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation combined with morning-evening supplementing therapy significantly improves clinical symptoms and pulmonary function,and reduces acute exacerbations and hospitalizations in patients with stable COPD of lung-kidney deficiency type.
